Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells.

@article{DiazMontero2009DailyIO,
  title={Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells.},
  author={C. Diaz-Montero and N. Paphitis and G. Onicescu and Ying Zhu and N. Verma and E. Garrett-Mayer and K. Schuhwerk and Cj Pazoles and S. Glueck and A. Montero},
  journal={Cancer Research},
  year={2009},
  volume={69},
  pages={2141}
}
  • C. Diaz-Montero, N. Paphitis, +7 authors A. Montero
  • Published 2009
  • Medicine
  • Cancer Research
  • CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2141 Background: Chemotherapy induced anemia is a common problem in breast cancer. Anemic events [Hgb<10 g/dL, use of erythropoietin stimulating agents (ESAs), or transfusion] are likely to occur in 30-40% of breast cancer patients (pts) receiving doxorubicin-cyclophosphamide (AC) and docetaxel (T). Owing to the increased risk of cancer mortality, tumor progression, and thrombovascular events associated with ESAs, other… CONTINUE READING
    5 Citations